학술논문
Marked Decreased Tracer Binding in 123 I-FP-CIT SPECT Scans From Lisdexafetamine Dismesylate Interaction: A Case Report.
Document Type
Academic Journal
Author
Miyagawa T; Departments of Neurology.; Vernon C; Radiology.; Przybelski SA; Quantitative Health Sciences.; Min HK; Radiology.; Fields JA; Psychiatry and Psychology, Mayo Clinic, Rochester, MN.; Kantarci K; Radiology.; Lowe V; Radiology.; Boeve BF; Departments of Neurology.
Source
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7607910 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-162X (Electronic) Linking ISSN: 03625664 NLM ISO Abbreviation: Clin Neuropharmacol Subsets: MEDLINE
Subject
Language
English
Abstract
Objectives: The objective of this case study is to raise awareness of potential 123 I-FP-CIT SPECT interference by lisdexafetamine dimesylate, a prodrug of d -amphetamine.
Methods: A 69-year-old man with Rapid Eye Movement sleep behavior disorder and mild cognitive impairment had been treated with lisdexafetamine dimesylate for attention-deficit/hyperactivity disorder. The patient had annual or biennial 123 I-FP-CIT SPECT evaluations after their baseline visit at 69 years old. Nigrostriatal dopamine transporter uptake was semiquantitatively evaluated with 123 I-FP-CIT SPECT using DaTQUANT 2.0 software. Lisdexafetamine dimesylate was discontinued 3 months before the sixth-year visit (76 years old) by his primary care provider.
Results: The patient had 4 123 I-FP-CIT SPECT scans with lisdexafetamine dimesylate and 2 scans after the discontinuation of lisdexafetamine dimesylate. The DaTQUANT z -scores of the putamen declined from -1.36 at the baseline visit to -3.02 at the fifth-year visit. After the discontinuation of lisdexafetamine dimesylate, DaTQUANT z -scores of the putamen increased to -0.63 at the sixth-year visit and remained in the normal range of -0.71 at the seventh-year visit.
Conclusions: This case suggests that lisdexafetamine dimesylate may have a strong interference with 123 I-FP-CIT SPECT, decreasing the tracer binding to the dopamine transporter and presenting false positive results.
Competing Interests: Conflicts of Interest and Source of Funding: J.A.F. serves as a paid consultant for Medtronic, Inc. K.K. serves as a paid consultant for Biogen and receives research support from Avid Radiopharmaceuticals, Eli Lilly. V.J.L. serves as a consultant for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc, AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). B.F.B. receives honoraria for SAB activities for the Tau Consortium and receives institutional research grant support from Alector, Biogen, Transposon, Cognition Therapeutics, and GE Healthcare. The other authors have no conflicts of interest to declare.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Methods: A 69-year-old man with Rapid Eye Movement sleep behavior disorder and mild cognitive impairment had been treated with lisdexafetamine dimesylate for attention-deficit/hyperactivity disorder. The patient had annual or biennial 123 I-FP-CIT SPECT evaluations after their baseline visit at 69 years old. Nigrostriatal dopamine transporter uptake was semiquantitatively evaluated with 123 I-FP-CIT SPECT using DaTQUANT 2.0 software. Lisdexafetamine dimesylate was discontinued 3 months before the sixth-year visit (76 years old) by his primary care provider.
Results: The patient had 4 123 I-FP-CIT SPECT scans with lisdexafetamine dimesylate and 2 scans after the discontinuation of lisdexafetamine dimesylate. The DaTQUANT z -scores of the putamen declined from -1.36 at the baseline visit to -3.02 at the fifth-year visit. After the discontinuation of lisdexafetamine dimesylate, DaTQUANT z -scores of the putamen increased to -0.63 at the sixth-year visit and remained in the normal range of -0.71 at the seventh-year visit.
Conclusions: This case suggests that lisdexafetamine dimesylate may have a strong interference with 123 I-FP-CIT SPECT, decreasing the tracer binding to the dopamine transporter and presenting false positive results.
Competing Interests: Conflicts of Interest and Source of Funding: J.A.F. serves as a paid consultant for Medtronic, Inc. K.K. serves as a paid consultant for Biogen and receives research support from Avid Radiopharmaceuticals, Eli Lilly. V.J.L. serves as a consultant for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc, AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). B.F.B. receives honoraria for SAB activities for the Tau Consortium and receives institutional research grant support from Alector, Biogen, Transposon, Cognition Therapeutics, and GE Healthcare. The other authors have no conflicts of interest to declare.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)